Nascent Biotech
Nascent Biotech is a Florida-based company focused on the development and delivery of human antibodies and cytokine responses for the treatment of cancer. The company leverages the natural human immune system to generate immunologically based therapeutics, aiming to develop safe, non-toxic, and specific biological drugs. Their flagship product, Pritumumab, is a proprietary monoclonal antibody targeting a novel antigen on cancer cells, and has received FDA orphan drug status. Nascent's approach involves mimicking the body's natural antibody and cellular responses by identifying and combining antibodies and cytokines into potent cocktails for multi-targeted disease attack, with applications spanning cancer, metabolic disorders, and infectious diseases.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Pritumumab
A fully human IgG1 monoclonal antibody clinical-stage candidate that binds a tumor-associated cell-surface antigen (ectodomain vimentin); developed for treatment of brain and other epithelial cancers. Has received orphan drug designation and completed Phase I safety cohorts.
CLNH5
Product page listed by the company; specific details were not provided in the supplied source content.
MultiPharm
Product/platform page listed by the company; specific details were not provided in the supplied source content.
Pritumumab
A fully human IgG1 monoclonal antibody clinical-stage candidate that binds a tumor-associated cell-surface antigen (ectodomain vimentin); developed for treatment of brain and other epithelial cancers. Has received orphan drug designation and completed Phase I safety cohorts.
CLNH5
Product page listed by the company; specific details were not provided in the supplied source content.
MultiPharm
Product/platform page listed by the company; specific details were not provided in the supplied source content.
Expertise Areas
- Monoclonal antibody therapeutics development
- Clinical trial management (Phase I and Phase II)
- CMC, bioprocessing and cGMP manufacturing
- Targeted immunotherapy and vaccine discovery
Key Technologies
- Monoclonal antibody therapeutics
- CHO cell expression systems
- Master cell bank (MCB) creation
- cGMP bioprocessing and scale-up
News & Updates
Nascent Biotech announced the opening of a Phase 1 clinical trial for Pritumumab targeting brain cancer.
Initial dosing has begun in the Phase 1 trial for brain cancer using Pritumumab.
Hoag Family Cancer Institute and Pickup Family Neurosciences Institute at Hoag collaborate with Nascent Biotech on a first-in-nation clinical trial for a novel immunotherapy for glioblastoma.
A study presented at the 2023 ASCO Annual Meeting on the Phase 1 trial of Pritumumab in brain cancer.
Nascent Biotech announced plans to start Phase II clinical trials for brain cancer using Pritumumab.
Pritumumab has received FDA orphan drug status, facilitating its development for rare conditions.
Nascent Biotech announced the opening of a Phase 1 clinical trial for Pritumumab targeting brain cancer.
Initial dosing has begun in the Phase 1 trial for brain cancer using Pritumumab.
Hoag Family Cancer Institute and Pickup Family Neurosciences Institute at Hoag collaborate with Nascent Biotech on a first-in-nation clinical trial for a novel immunotherapy for glioblastoma.
A study presented at the 2023 ASCO Annual Meeting on the Phase 1 trial of Pritumumab in brain cancer.
Nascent Biotech announced plans to start Phase II clinical trials for brain cancer using Pritumumab.
Pritumumab has received FDA orphan drug status, facilitating its development for rare conditions.